KEI and UACT comments on the prospective grant of exclusive licenses to Sinotau and MTTI

On August 27, 2018, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) filed comments to the NIH regarding the prospective grant of two separate exclusive licenses to Sinotau Pharmaceutical Group and Molecular Targeting Technologies, Inc. (MTTI),… Continue Reading

KEI Comments to the NIH on Exclusive License of AAV Technology to Children’s Medical Research Institute in Australia

Knowledge Ecology International (KEI) submitted comments on Wednesday July 14, 2021 to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Adeno-Associated Virus Polynucleotides, Polypeptides and Virions” (86 FR 34246). The rights to technology… Continue Reading

KEI and UACT Joint Comments to the NIH Regarding Exclusive License to Syncopation for CAR Therapy

Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the National Institutes of Health (NIH) on Friday July 9, 2021 regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Monospecific… Continue Reading

KEI Comments on NIH Exclusive License to Panacea for Gene Therapy

On Friday July 9, 2021, Knowledge Ecology International submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Delivery of a Corrective Glucose-6-Phosphatase-Alpha Gene to Treat Glycogen Storage Disease Type 1a (GSD-Ia)… Continue Reading

Biden Administration asked to clarify scope of sanctions exceptions for Cuba’s vaccine program, and to support the evaluation and registration of its COVID-19 vaccines

On June 28, 2021, KEI sent a memorandum to Gayle E Smith (State), Eric Lander (OSTP), Loyce Pace (HHS) and Samantha Power (USAID), asking the U.S. government to clarify that its sanctions against Cuba do not extend to activities and… Continue Reading

KEI Comments Regarding NIH Exclusive License to Lyell Immunopharma for Cell Therapy Cancer Treatment

On June 8, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) concerning the “Prospective Grant of an Exclusive Patent License: Methods and Compositions for Adoptive Cell Therapy” (86 FR 27852). The inventions to be… Continue Reading

KEI Comments Concerning NIH Exclusive License to Kantum Pharma

Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) on June 8, 2021 regarding the “Prospective Grant of an Exclusive Patent License: P2Y14 Receptor Antagonists To Treat Kidney and Lung Inflammation” (86 FR 27858). The license… Continue Reading